威尔药业(603351) - 2020 Q1 - 季度财报

Financial Performance - Operating income decreased by 26.95% to CNY 155,405,905.89 compared to the same period last year[8] - Net profit attributable to shareholders fell by 15.67% to CNY 32,186,509.68 year-on-year[8] - Basic earnings per share decreased by 22.73% to CNY 0.34 compared to the same period last year[8] - The weighted average return on equity decreased by 33.33 percentage points to 2.56%[8] - Total operating revenue for Q1 2020 was CNY 155,405,905.89, a decrease of 27% compared to CNY 212,735,636.49 in Q1 2019[25] - Net profit for Q1 2020 was CNY 32,186,509.68, a decline of 15.5% from CNY 38,166,687.25 in Q1 2019[26] - The net profit for Q1 2020 was CNY 32,119,266.56, down 18.7% from CNY 39,510,573.29 in the same period last year[29] - The total comprehensive income for Q1 2020 was CNY 32,119,266.56, down from CNY 39,510,573.29 in Q1 2019[29] Assets and Liabilities - Total assets increased by 1.59% to CNY 1,481,408,055.91 compared to the end of the previous year[8] - The company's total assets as of March 31, 2020, amounted to CNY 1,455,563,707.61, an increase from CNY 1,430,405,326.10 at the end of 2019[23] - The total liabilities decreased to ¥207,759,593.55 from ¥217,055,335.80, indicating a reduction in financial obligations[18] - The company's total liabilities were CNY 173,970,642.68 as of March 31, 2020, down from CNY 181,178,274.62 at the end of 2019[23] - The total amount of short-term borrowings was CNY 102,217,300.17[42] Cash Flow - Net cash flow from operating activities decreased by 39.43% to CNY 20,698,657.55 compared to the previous year[8] - The cash flow from operating activities for Q1 2020 was CNY 20,698,657.55, a decrease of 39.5% from CNY 34,173,470.33 in Q1 2019[30] - The company reported a net cash outflow from investing activities of CNY -60,152,005.62 in Q1 2020, compared to CNY -10,724,150.02 in Q1 2019[31] - The net cash flow from investment activities was -¥16,563,133.10, an improvement from -¥262,990,567.02 in Q1 2019[34] - Cash and cash equivalents at the end of Q1 2020 were CNY 155,712,266.00, down from CNY 607,036,013.89 at the end of Q1 2019[31] Shareholder Information - The total number of shareholders reached 9,684 as of the report date[11] - The top shareholder, Wu Renrong, holds 14.17% of the shares with 13,229,986 shares[11] - The equity attributable to shareholders increased to CNY 1,281,593,064.93 as of March 31, 2020, compared to CNY 1,249,227,051.48 at the end of 2019[23] Operational Metrics - The company's accounts receivable decreased by 31.54% to ¥49,335,587.57 compared to ¥72,060,401.95 in the previous year, attributed to a decline in operating revenue[13] - Prepayments dropped by 31.55% to ¥11,316,938.57 from ¥16,531,998.21 due to reduced production volume[13] - Operating costs fell by 31.41% to ¥92,574,941.20 from ¥134,969,207.90, driven by decreased sales volume and lower raw material prices[14] - The company reported a significant increase in other receivables by 448.06% to ¥920,360.40 from ¥167,931.36, due to increased customer bidding deposits and export tax refunds[13] - The company incurred a credit impairment loss of CNY 1,220,256.40 in Q1 2020, compared to a gain of CNY -721,899.40 in Q1 2019[29] Research and Development - Research and development expenses for Q1 2020 were CNY 7,810,372.57, an increase from CNY 6,766,200.94 in Q1 2019[26] - Research and development expenses for Q1 2020 were CNY 7,388,365.50, an increase of 13.4% from CNY 6,510,221.73 in Q1 2019[28] Financial Standards and Changes - The company implemented new revenue recognition standards effective January 1, 2020, resulting in a reclassification of CNY 5,164,557.93 from advance receipts to contract liabilities[43] - The company executed a new revenue recognition standard, resulting in a reclassification of prepayments to contract liabilities, with contract liabilities reported at ¥4,655,311.44[14]